Late lumen loss of drug eluting stents versus bare mental stents for saphenous vein graft intervention

Journal of Clinical Rehabilitative Tissue Engineering Research

Volumn 12, Issue 35, 2008, Pages 6971-6975

  Guo, Jin Cheng ^a   Xu, Min ^a   Wang, Guo Zhong ^a   Ma, Chang Sheng ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; PACLITAXEL; RAPAMYCIN; STAINLESS STEEL; TICLOPIDINE;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INTERMETHOD COMPARISON; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; RETROSPECTIVE STUDY; SAPHENOUS VEIN GRAFT; STENT; VEIN GRAFT DISEASE;

EID: 55049110452     PISSN: 16738225     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Hoye A, Lemos PA, Arampatzis CA, et al. Effectiveness of the sirolimus-eluting stent in the treatment of patients with a prior history of coronary artery bypass graft surgery. Coron Artery Dis 2004;15(3): 171-175
2. Mishra S, Wolfram RM, Torguson R, et al. Comparison of effectiveness and safety of drug-eluting stents versus vascular brachytherapy for saphenous vein graft in-stent restenosis. Am J Cardiol 2006;97(9):1303-1307
3. Ge L, Iakovou I, Sangiorgi GM, et al. Treatment of saphenous vein graft lesions with drug-eluting stents: immediate and midterm outcome. J Am Coll Cardiol 2005;45(7):989-994
4. Lee MS, Shah AP, Aragon J, et al. Drug-eluting stenting is superior to bare metal stenting in saphenous vein grafts. Catheter Cardiovasc Interv 2005;66(4):507-511
5. Minutello RM, Bhagan S, Sharma A, et al. Long-term clinical benefit of sirolimus-eluting stents compared to bare metal stents in the treatment of saphenous vein graft disease. J Interv Cardiol 2007;20(6):458-465
6. Ryan TJ, Faxon DP, Gunnar RM, et al. Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). Circulation 1988;78(2):486-502
7. Goldman S, Zadina K, Moritz T, et al. Long-term patency of saphenous vein and left internal mammary artery grafts after coronary artery bypass surgery: results from a Department of Veterans Affairs Cooperative Study. J Am Coll Cardiol 2004;44(11):2149-2156
8. Gaudino M, Cellini C, Pragliola C, et al. Arterial versus venous bypass grafts in patients with in-stent restenosis. Circulation 2005;112(9 Suppl):I265-269
9. Presbitero P, Zavalloni D, Pagnotta P, et al. DES implantation in saphenous vein and left internal mammary grafts. Minerva Cardioangiol 2008;56(1):79-87
10. Lytle BW. Prolonging patency - choosing coronary bypass grafts. N Engl J Med 2004;351(22):2262-2264
11. Mennander A, Angervuori T, Huhtala H, et al. Positive family history of coronary atherosclerosis and serum triglycerides may predict repeated coronary artery bypass surgery. Scand Cardiovasc J 2005;39(4):225-228
12. Morrison DA, Sethi G, Sacks J, et al. Percutaneous coronary intervention versus repeat bypass surgery for patients with medically refractory myocardial ischemia: AWESOME randomized trial and registry experience with post-CABG patients. J Am Coll Cardiol 2002;40(11):1951-1954,
13. Pratsos A, Fischman DL, Savage MP. Restenosis in saphenous vein grafts. Curr Interv Cardiol Rep 2001;3(4):287-295
14. de Jaegere PP, van Domburg RT, Feyter PJ, et al. Long-term clinical outcome after stent implantation in saphenous vein grafts. J Am Coll Cardiol 1996;28(1):89-96
15. Savage MP, Douglas JS Jr, Fischman DL, et al. Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. Saphenous Vein De Novo Trial Investigators. N Engl J Med 1997;337(11):740-747
16. Wöhrle J, Nusser T, Kestler HA, et al. Comparison of the slow-release polymer-based paclitaxel-eluting Taxus-Express stent with the bare-metal Express stent for saphenous vein graft interventions. Clin Res Cardiol 2007;96(2):70-76
17. Ellis SG, Kandzari D, Kereiakes DJ, et al. Utility of sirolimus-eluting Cypher stents to reduce 12-month target vessel revascularization in saphenous vein graft stenoses: results of a multicenter 350-patient case-control study. J Invasive Cardiol 2007;19(10):404-409
18. Vermeersch P, Agostoni P, Verheye S, et al. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial. J Am Coll Cardiol 2006;48(12):2423-2431
19. Chu WW, Rha SW, Kuchulakanti PK, et al. Efficacy of sirolimus-eluting stents compared with bare metal stents for saphenous vein graft intervention. Am J Cardiol 2006;97(1):34-37
20. Vignali L, Saia F, Manari A, et al. Long-term outcomes with drug-eluting stents versus bare metal stents in the treatment of saphenous vein graft disease (results from the Registro Regionale AngiopLastiche Emilia-Romagna registry). Am J Cardiol 2008;101(7): 947-952
21. Keeley EC, Velez CA, O'Neill WW, et al. Long-term clinical outcome and predictors of major adverse cardiac events after percutaneous interventions on saphenous vein grafts. J Am Coll Cardiol 2001;38(3): 659-665
22. Karha J, Gurm HS, Rajagopal V, et al. Use of platelet glycoprotein IIb/ IIIa inhibitors in saphenous vein graft percutaneous coronary intervention and clinical outcomes. Am J Cardiol 2006;98(7):906-910